Wilsey Asset Management Inc. Boosts Stock Position in Pfizer Inc. $PFE

Wilsey Asset Management Inc. lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 17.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,390,058 shares of the biopharmaceutical company’s stock after buying an additional 202,641 shares during the quarter. Pfizer makes up approximately 4.9% of Wilsey Asset Management Inc.’s investment portfolio, making the stock its 13th largest position. Wilsey Asset Management Inc.’s holdings in Pfizer were worth $33,473,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in PFE. Vermillion Wealth Management Inc. increased its holdings in Pfizer by 19.4% in the 1st quarter. Vermillion Wealth Management Inc. now owns 2,352 shares of the biopharmaceutical company’s stock worth $66,000 after acquiring an additional 382 shares in the last quarter. Triad Wealth Partners LLC lifted its holdings in Pfizer by 1.9% during the fourth quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company’s stock valued at $510,000 after purchasing an additional 386 shares in the last quarter. Eagle Capital Management LLC lifted its holdings in Pfizer by 0.3% during the first quarter. Eagle Capital Management LLC now owns 126,573 shares of the biopharmaceutical company’s stock valued at $3,554,000 after purchasing an additional 390 shares in the last quarter. ETF Store Inc. grew its position in shares of Pfizer by 3.8% in the fourth quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company’s stock valued at $272,000 after purchasing an additional 396 shares during the period. Finally, Delta Financial Advisors LLC increased its stake in shares of Pfizer by 1.6% during the first quarter. Delta Financial Advisors LLC now owns 25,266 shares of the biopharmaceutical company’s stock worth $709,000 after purchasing an additional 398 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Q2 earnings beat and guidance increase: Pfizer reported adjusted earnings of $0.77 per share versus the $0.68 consensus estimate, while revenue of $15.03 billion exceeded expectations of $14.40 billion. Management raised the low end of its 2026 revenue outlook, supported by Eliquis and other non-COVID products. Pfizer Q2 Earnings Call Highlights Non-COVID Growth and Cost Cuts
• Positive Sentiment: Cost savings and pipeline support: Pfizer expanded its cost-reduction target, providing a potential lift to future margins and cash flow. Analysts also highlighted continued growth in newer products and a broader R&D pipeline as offsets to declining COVID revenue. PFE Q2 Deep Dive: New Products Offset COVID Decline, R&D Pipeline Expands
• Positive Sentiment: Clinical catalysts: Pfizer reported positive Phase 3 data for LITFULO in vitiligo and announced progress in a pediatric COVID booster study. It also completed a Phase 1 study of PF-07328948, adding incremental support to its longer-term pipeline narrative. Pfizer Reports Positive Phase 3 LITFULO Data in Vitiligo
• Neutral Sentiment: Analyst view remains mixed: Some coverage describes Pfizer as attractive for income investors because of its high dividend yield and potential undervaluation, while RBC Capital maintained a Hold rating. Investors remain focused on execution and the sustainability of the recovery. RBC Capital Remains a Hold on Pfizer
• Negative Sentiment: COVID and pipeline risks persist: COVID pill revenue reportedly fell 95%, and setbacks surrounding Pfizer’s obesity program, along with upcoming patent expirations, continue to raise concerns about long-term growth. These risks explain why the market’s response remains measured despite the earnings beat. Pfizer Covid Pill Revenue Plunges 95%

Pfizer Trading Up 1.4%

Shares of Pfizer stock opened at $26.18 on Friday. The stock has a market cap of $149.24 billion, a P/E ratio of 34.45 and a beta of 0.34. The stock’s 50 day simple moving average is $25.01 and its 200-day simple moving average is $26.16. Pfizer Inc. has a 1-year low of $23.58 and a 1-year high of $28.75. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.94.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The business had revenue of $15.03 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same period in the prior year, the business earned $0.78 earnings per share. The business’s revenue was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts predict that Pfizer Inc. will post 2.94 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.6%. Pfizer’s dividend payout ratio (DPR) is 226.32%.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. Guggenheim reduced their price target on shares of Pfizer from $36.00 to $35.00 and set a “buy” rating for the company in a research report on Monday, July 13th. Wolfe Research reiterated an “underperform” rating and issued a $26.00 price objective on shares of Pfizer in a report on Thursday, May 14th. Weiss Ratings reiterated a “hold (c)” rating on shares of Pfizer in a research note on Monday. HSBC cut Pfizer from a “buy” rating to a “hold” rating and reduced their target price for the company from $32.00 to $28.00 in a report on Monday, July 6th. Finally, Royal Bank Of Canada raised Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price target on the stock in a research note on Tuesday, June 9th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $28.50.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.